Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Joseph A Messana, Stanley S Schwartz & Raymond R Townsend. (2017) An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes. Vascular Health and Risk Management 13, pages 43-54.
Read now
Read now
Articles from other publishers (7)
Siddhartha Dutta, Tarun Kumar, Surjit Singh, Sneha Ambwani, Jaykaran Charan & ShobanB Varthya. (2022) Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis. Journal of Family Medicine and Primary Care 11:3, pages 927.
Crossref
Crossref
Shih-Wei Lai, Kuan-Fu Liao, Yu-Hung Kuo, Cheng-Li Lin, Chiu-Shong Liu & Bing-Fang Hwang. (2021) A Head-To-Head Comparison of Benzbromarone and Allopurinol on the Risk of Type 2 Diabetes Mellitus in People With Asymptomatic Hyperuricemia. Frontiers in Pharmacology 12.
Crossref
Crossref
Zheng Kang LumWei Yann See TohSze Mian LimKhairul Dzakirin Bin RusliShaikh Abdul Kader Kamaldeen Abdul ShakoorKeith Yu Kei TsouDaniel Ek Kwang ChewRinkoo DalanSing Cheer KwekNoorani OthmanJoyce Xia LianJoyce Yu-Chia Lee. (2018) Development of a Collaborative Algorithm for the Management of Type 2 Diabetes during Ramadan: An Anchor on Empowerment. Diabetes Technology & Therapeutics 20:10, pages 698-703.
Crossref
Crossref
Karun Badwal, Tooba Tariq & Diane Peirce. (2018) Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis. Case Reports in Endocrinology 2018, pages 1-4.
Crossref
Crossref
Andrea Natali, Lorenzo Nesti, Iacopo Fabiani, Enrico Calogero & Vitantonio Di Bello. (2017) Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovascular Diabetology 16:1.
Crossref
Crossref
Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, Joo Young Nam, Kyu Jeung Ahn, Tae Keun Oh, Hyoung Woo Lee, Dae Ho Lee, Jaetaek Kim, Choon Hee Chung, Tae Sun Park, Byung Joon Kim, Seok Won Park, Hyeong Kyu Park, Kwang Jae Lee, Sang-Wook Kim, Jeong Hyun Park, Kwan Pyo Ko, Chong Hwa Kim, Hyunjin Lee, Hak Chul Jang & Kyong Soo Park. (2017) Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-. Diabetes, Obesity and Metabolism 19:5, pages 635-643.
Crossref
Crossref
Sevim Kahraman, Erin R. Okawa & Rohit N. Kulkarni. (2016) Is Transforming Stem Cells to Pancreatic Beta Cells Still the Holy Grail for Type 2 Diabetes?. Current Diabetes Reports 16:8.
Crossref
Crossref